返回 
加入收藏
醋酸亮丙瑞林治疗子宫内膜异位症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 醋酸亮丙瑞林治疗子宫内膜异位症的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨醋酸亮丙瑞林治疗子宫内膜异位症的临床疗效及安全性。方法：将66例子宫内膜异位症患者按照随机数字表法分为观察组（37例）和对照组（29例）。观察组患者给予注射用醋酸亮丙瑞林微球，于患者月经周期开始的第1～5天进行第1次给药（切除子宫者可自行选择给药时间），每次3.75 mg，于上臂、腹部或臀部皮下注射，之后每4周注射1次，每次给药算1个疗程。对照组患者给予炔雌醇环丙孕酮片口服，每天1片，服药3周后停药1周为1个疗程。两组患者均根据耐受情况或临床症状改善程度治疗3～5个疗程。比较两组患者的临床主观症状改善情况，治疗前后卵泡生成激素（FSH）、黄体生成激素（LH）、雌二醇（E2）等激素水平的变化，并记录不良反应发生情况和患者月经复潮时间。结果：观察组和对照组分别有2、1例患者脱落。治疗后，观察组患者临床主观症状改善的总有效率为97.14％，显著高于对照组的75.00％，差异有统计学意义（P＜0.05）。治疗前，两组患者的FSH、LH、E2水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者的FSH、LH、E2水平均较治疗前显著下降，且观察组患者下降幅度显著大于对照组，差异有统计学意义（P＜0.05）。治疗期间，观察组患者的不良反应总发生率为20.00％，与对照组（21.42％）比较，差异无统计学意义（P＞0.05）。观察组患者停药后月经复潮时间为（89.75±3.34）d，与对照组[（88.46±2.94）d]比较，差异无统计学意义（P＞0.05）。结论：醋酸亮丙瑞林可有效改善子宫内膜异位症患者的临床主观症状，降低患者体内FSH、LH、E2等激素水平，且治疗期间的不良反应程度较轻，也不影响患者的月经复潮时间。 |
| ABSTRACT： | OBJECTIVE： To discuss clinical efficacy and safety of leuprolide acetate in the treatment of endometriosis. METHODS： 66 endometriosis patients were divided into observation group （37 cases） and control group （29 cases） according to random number table method. Observation group was treated with Leuprolide acetate microsphere for injection， 3.75 mg/time， on the upper arm， abdomen or buttocks since the first-fifth day of menstrual cycle （administration time was available at hysterectomized patients disposal）， and then every 4 weeks； one administration was recognized as a treatment course. Control group was treated with Ethinyl estradiol cyproterone tablet orally， 1 tablets per day for 3 weeks， one week drug withdrawal， as a treatment course. 2 groups were given 3-5 courses of treatment according to their tolerance or the improvement of clinical symptoms. The improvement of clinical symptoms were compared between 2 groups， and the levels of FSH， LH and E2 were compared before and after treatment； the occurrence of ADR and the time of the return of menses were recorded. RESULTS： 2 patients in observation group and 1 patient in control group withdrew from the test. After treatment， total effective rate was 97.14％ in observation group， which was significantly higher than 75.00％ in control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of FSH， LH and E2 between 2 groups （P＞0.05）. After treatment， the levels of FSH， LH and E2 were decreased significantly， and the observation group was more significant than the control group， with statistical significance （P＜0.05）. Total incidence of ADR was 20.00％ in observation group， compared to control group （21.42％）， there was no statistical significance （P＞0.05）. The time of the return of menses in observation group was （89.75±3.34） d after drug withdrawal， compared to control group [（88.46±2.94）d]， there was no statistical significance （P＞0.05）. CONCLUSIONS： Leuprolide acetate can effectively improve clinical symptoms of patients with endometriosis， and reduce the levels of FSH， LH and E2 with slight ADR， and it doesn’t influence the time of the return of menses. |
| 期刊： | 2016年第27卷第26期 |
| 作者： | 张余芳，林尧，卢秀英，蔡志善 |
| AUTHORS： | ZHANG Yufang，LIN Yao，LU Xiuying，CAI Zhishan |
| 关键字： | 醋酸亮丙瑞林；子宫内膜异位症；临床疗效；安全性 |
| KEYWORDS： | Leuprolide acetate； Endometriosis； Clinical efficacy； Salety |
| 阅读数： | 840 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
